Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI3030
- Development stage
- Preclinical
- Lead developer
- Innovent Biologics
- Modality
- Peptides, Antibody-Based Therapeutics
01
Overview
**IBI3030** is an Innovent antibody-peptide conjugate in preclinical development for cardiometabolic disease. It combines an anti-proprotein convertase subtilisin/kexin type 9 antibody, intended to prevent PCSK9-mediated low-density lipoprotein receptor degradation and lower LDL cholesterol, with a peptide triagonist that activates glucagon-like peptide 1 receptor, glucagon receptor, and glucose-dependent insulinotropic polypeptide receptor. In preclinical mouse, rat, and non-human-primate studies, IBI3030 reduced LDL cholesterol and body weight and improved glucose tolerance and metabolic risk markers.
- Other names
- IBI 3030IBI3030IBI-3030PCSK9-GGGPCSK-9-GGGPCSK 9-GGG
02
Targets
Beyond the preview
Go deeper on IBI3030.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI3030.